Innoviva, Inc. (INVA)
NASDAQ: INVA · Real-Time Price · USD
19.96
-0.43 (-2.11%)
Jun 27, 2025, 4:00 PM - Market closed
Innoviva Employees
Innoviva had 127 employees as of December 31, 2024. The number of employees increased by 15 or 13.39% compared to the previous year.
Employees
127
Change (1Y)
15
Growth (1Y)
13.39%
Revenue / Employee
$2,912,157
Profits / Employee
-$470,268
Market Cap
1.25B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
INVA News
- 16 days ago - FDA Grants Priority Review for Zoliflodacin New Drug Application for the Treatment of Uncomplicated Gonorrhea and Assigns Target PDUFA Date of December 15, 2025 - Business Wire
- 18 days ago - Innoviva Specialty Therapeutics Receives FDA New Drug Application Acceptance for Zoliflodacin, a First-in-Class Oral Antibiotic for Uncomplicated Gonorrhea in Adults - Business Wire
- 25 days ago - Innoviva to Participate in Upcoming Investor Conferences - Business Wire
- 5 weeks ago - ZEVTERA® (ceftobiprole), an Advanced-Generation Cephalosporin Antibiotic Now Commercially Available in the U.S. to Treat Three Types of Bacterial Infections - Business Wire
- 5 weeks ago - Basilea announces commercial availability of antibiotic Zevtera® (ceftobiprole) in the United States - GlobeNewsWire
- 7 weeks ago - Innoviva Reports First Quarter 2025 Financial Results; Highlights Recent Company Progress - Business Wire
- 3 months ago - Armata Pharmaceuticals Announces $10 Million Secured Credit Agreement with Innoviva - PRNewsWire
- 4 months ago - Innoviva to Participate in the Barclays 27th Annual Global Healthcare Conference - Business Wire